Gossamer Bio Earnings Call Transcripts
Fiscal Year 2026
-
Phase III PROSERA data showed clinically meaningful improvements in PAH, supported by robust CT-FRI imaging evidence of multi-compartment lung remodeling. Cost reductions and a convertible note exchange have extended cash runway and improved capital structure, with NDA submission targeted for September 2026.
-
The phase III PROSERA trial of seralutinib in PAH showed a 13.3-meter placebo-adjusted improvement in 6MWD at week 24 (p=0.032), missing the primary endpoint. Clinically meaningful and statistically significant benefits were observed in high-risk and CTD subgroups, with a favorable safety profile. Regulatory discussions and further analyses are planned.
Fiscal Year 2025
-
Seralutinib’s phase 3 Prosera trial is set for a key data readout in February, with a focus on sicker patients and a differentiated safety profile. Commercial launch is targeted for late Q2 2027, with expansion into PH-ILD and a strengthened pipeline through recent asset acquisition.
-
Major phase 3 data for seralutinib in PAH is expected in February, with a second phase 3 in PH-ILD planned by year-end, targeting a combined market over $20 billion. Seralutinib's strong safety and efficacy profile, plus the addition of RT234, positions the pipeline for global leadership.
-
Transitioning to commercialization, the company is preparing for a 2027 launch of seralutinib, with robust phase 3 trials in PAH and PH-ILD. Strong efficacy, safety, and operational synergies are expected to support market entry and expansion into new indications.
-
Copperwood is advancing toward construction with full permits, detailed engineering, and strong community and legislative support. Environmental mitigation and metallurgical testing are underway, with project financing targeted for early 2026 and new federal funding opportunities expected.
-
PROSERA phase III enrollment is nearly complete, targeting high-risk PAH patients, with top-line results expected in February 2026. Financials show a strong cash position and improved net loss, supporting operations into 2027. Seralutinib is positioned for significant commercial impact in PAH and PH-ILD.
-
Phase 3 enrollment for PAH is set to complete in Q2 2024, with top-line data expected in Q4. Seralutinib is positioned for best-in-class safety and efficacy, targeting a $10-15 billion market with launches planned for 2027 and 2029.
-
Phase III enrollment for pulmonary hypertension is on track, with top-line data expected in Q4 and a 2027 launch targeted. Seralutinib differentiates itself with strong safety, efficacy, and imaging data, and a global enrollment strategy positions it well against competitors.
-
Seralutinib, an inhaled therapy for pulmonary hypertension, has shown sustained efficacy and a favorable safety profile in clinical trials, with a large market opportunity and strong financial backing. Phase III enrollment is expected to complete in Q2 2024, with top-line data in Q4 2024.
Fiscal Year 2024
-
PROSERA enrollment is on track for Q2 2025 completion, with data expected in Q4. Seralutinib is positioned for broad use in PAH, supported by robust safety and efficacy data, and commercial launch preparations are underway with Chiesi. PH-ILD program is advancing with regulatory alignment expected in 2025.
-
Seralutinib is advancing through global phase III trials for PAH and PH-ILD, with promising efficacy and safety data, and a commercial launch targeted for 2027. Strategic partnership with Chiesi enhances global reach, while a strong cash position supports ongoing development.
-
Seralutinib shows durable efficacy and safety in PAH, with phase III PROSERA enrolling globally and targeting sicker patients. The Chiesi partnership accelerates PH-ILD development and expands market reach, while regulatory alignment and strong trial design support future growth.